Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)
Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)
复制标题
DOI：
10.1016/s0014-5793(03)00523-4
复制
发表时间：
2003-06-19
期刊：
影响因子：
3.5
通讯作者：
Lage, H
中科院分区：
文献类型：
--
作者：
Nieth, C;Priebsch, A;Lage, H
为了逆转MDR 1基因依赖的多药耐药（MDR），设计了两种小干扰RNA（siRNA）构建体，通过RNA干扰来抑制MDR 1表达。用siRNA双链体处理人胰腺癌（EPP 85 - 181 RDB）和胃癌（EPG 85 - 257 RDB）细胞。在这两种细胞系统中，siRNA可以特异性地抑制MDR 1在mRNA和蛋白水平上的表达高达91%。对柔红霉素的耐药性降低至89%（EPP 85 - 181 RDB）或58%（EPG 85 - 257 RDB）。这些数据表明，这种方法可能适用于癌症患者作为一种特定的手段，以扭转肿瘤与P-糖蛋白依赖性MDR表型回到药物敏感的。(C)2003年欧洲生物化学学会联合会。由Elsevier Science B. V.出版，版权所有。
For reversal of MDR1 gene-dependent multidrug resistance (MDR), two small interfering RNA (siRNA) constructs were designed to inhibit MDR1 expression by RNA interference. SiRNA duplexes were used to treat human pancreatic carcinoma (EPP85-181RDB) and gastric carcinoma (EPG85-257RDB) cells. In both cellular systems, siRNAs could specifically inhibit MDR1 expression up to 91% at the mRNA and protein levels. Resistance against daunorubicin was decreased to 89% (EPP85-181RDB) or 58% (EPG85-257RDB). The data indicate that this approach may be applicable to cancer patients as a specific means to reverse tumors with a P-glycoprotein-dependent MDR phenotype back to a drug-sensitive one. (C) 2003 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.